Overview

Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer

Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited. The investigators hypothesize that gabapentin could be used to delay or reduce treatment-related pain, reliance on opioid medication, and improve the quality of life for these patients.
Phase:
Phase 3
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Gabapentin
gamma-Aminobutyric Acid